» Articles » PMID: 25873042

The Dopamine Theory of Addiction: 40 Years of Highs and Lows

Overview
Specialty Neurology
Date 2015 Apr 16
PMID 25873042
Citations 218
Authors
Affiliations
Soon will be listed here.
Abstract

For several decades, addiction has come to be viewed as a disorder of the dopamine neurotransmitter system; however, this view has not led to new treatments. In this Opinion article, we review the origins of the dopamine theory of addiction and discuss the ability of addictive drugs to elicit the release of dopamine in the human striatum. There is robust evidence that stimulants increase striatal dopamine levels and some evidence that alcohol may have such an effect, but little evidence, if any, that cannabis and opiates increase dopamine levels. Moreover, there is good evidence that striatal dopamine receptor availability and dopamine release are diminished in individuals with stimulant or alcohol dependence but not in individuals with opiate, nicotine or cannabis dependence. These observations have implications for understanding reward and treatment responses in various addictions.

Citing Articles

Opioidergic modulation of monetary incentive delay fMRI responses.

Turton S, Hawkins P, Muller-Pollard C, Zois E, Conrod P, Zelaya F Psychopharmacology (Berl). 2025; .

PMID: 40053107 DOI: 10.1007/s00213-025-06753-7.


Effects of GLP-1 Receptor Agonists in Alcohol Use Disorder.

Klausen M, Knudsen G, Vilsboll T, Fink-Jensen A Basic Clin Pharmacol Toxicol. 2025; 136(3):e70004.

PMID: 39891507 PMC: 11786240. DOI: 10.1111/bcpt.70004.


Neuroscience of cancer: unraveling the complex interplay between the nervous system, the tumor and the tumor immune microenvironment.

Huang Q, Hu B, Zhang P, Yuan Y, Yue S, Chen X Mol Cancer. 2025; 24(1):24.

PMID: 39825376 PMC: 11740516. DOI: 10.1186/s12943-024-02219-0.


Does semaglutide reduce alcohol intake in Danish patients with alcohol use disorder and comorbid obesity? Trial protocol of a randomised, double-blinded, placebo-controlled clinical trial (the SEMALCO trial).

Klausen M, Kuzey T, Pedersen J, Justesen S, Rasmussen L, Knorr U BMJ Open. 2025; 15(1):e086454.

PMID: 39779270 PMC: 11749217. DOI: 10.1136/bmjopen-2024-086454.


The potential of non-psychedelic 5-HT2A agents in the treatment of substance use disorders: a narrative review of the clinical literature.

Pulido-Saavedra A, Borelli A, Kitaneh R, Alrafayia M, Jalilian-Khave L, Funaro M Expert Opin Pharmacother. 2024; 26(2):133-146.

PMID: 39708346 PMC: 11786980. DOI: 10.1080/14656566.2024.2446623.